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Context-independent anti-hypusine antibodies that bind to the post-translational modification (PTM), hypusine,
with minimal dependence on flanking amino acid sequences, were identified. The antibodies bind to both
hypusine and deoxyhypusine or selectively to hypusine but not to deoxyhypusine. Phage display was used to
further enhance the affinity of the antibodies. Affinity maturation of these anti-hypusine antibodies improved their
performance in affinity capture of the only currently known hypusinated protein, eukaryotic translation initiation
factor 5A. These anti-hypusine antibodies may have utility in the identification of novel hypusinated proteins.
Crystal structures of the corresponding Fab fragments were determined in complex with hypusine- or
deoxyhypusine-containing peptides. The hypusine or deoxyhypusine moiety was found to reside in a deep
pocket formed between VH and VL domains of the Fab fragments. Interaction between the antibodies and
hypusine includes an extensive hydrogen bond network. These are, to our knowledge, the first reported
structures of context-independent anti-PTM antibodies in complex with the corresponding PTM.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The unusual amino acid, hypusine [Nε-(4-amino-2-
hydroxybutyl)lysine], is a post-translationalmodification
(PTM) of lysine. Eukaryotic translation initiation factor
5A (eIF-5A) is currently the only naturally occurring
protein that has been reported to contain hypusine
[1,2]. Themodification of eIF-5Awith hypusine involves
two enzymatic reactions. Firstly, deoxyhypusine
synthase (DHS) transfers the butylamine moiety of
spermidine to the ε-amino group of one specific lysine
residue of eIF-5A (K50 for the human protein), resulting
in deoxyhypusine. Secondly, hypusine biosynthesis
is completed by hydroxylation catalyzed by deoxyhy-
pusine hydroxylase (DOHH) [3]. Hypusinated eIF-5A
appears to be the active form since most known
functions ofeIF-5A, such as translational elongation,
RNA binding, and ribosome association, are depen-
dent upon hypusination [4,5].
The amino acid sequence of eIF-5A, as well as DHS
andDOHH, is highly conserved throughout eukaryotes,
Authors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/4.0/).and deoxyhypusine/hypusine is absolutely required for
cell proliferation in archaea and eukaryotes [6,7]. The
lysine residue (K50) that is converted into hypusine
and the amino acid sequences surrounding this
modification site are highly conserved, underscoring
the importance of this unusual protein modification
throughout eukaryotic evolution. Although deoxyhy-
pusine and hypusine have not been identified in
bacteria, EF-P, the bacterial ortholog of eIF-5A,
undergoes a different PTM, namely β-lysylation
that converts K34 into β-lysyl-lysine. K34 in bacterial
EF-P corresponds to the hypusine modification site of
eIF-5A [8]. These observations underscore the
importance of the hypusine-like modifications.
Different PTMs, including phosphorylation, acetyla-
tion, and methylation, have each been identified on a
wide range of different proteins and regulate a variety
of protein functions that are critical to support life. This
led us to hypothesize that additional hypusinated
proteins may exist. However, no other hypusinated
proteins have yet been reported in spite of extensive
is an open access article under the CC BY-NC-ND license
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Table 1. Summary of peptides used for immunization,
screening, and crystallization.
Application and
name
Sequence
Immunization
I1-Hpu Hpu -PEG6-C
I2-Hpu GSG-Hpu-GSG-PEG6-C
Screening
P1-Hpu biotin-PEG6-GSG-Hpu-GSG
P1-deoxy biotin-PEG6-GSG-deoxyHpu-GSG
P1 biotin-PEG6-GSG-K-GSG
P2-Hpu biotin-PEG6-STSKTG-Hpu-HGHAK
P2-deoxy biotin-PEG6-STSKTG-deoxyHpu-HGHAK
P2 biotin-PEG6-STSKTG-K-HGHAK
P3-Hpu biotin-GG-DEEAL-Hpu-QLAEWVS
P3 biotin-GG-DEEAL-K-QLAEWVS
P4-Hpu biotin-GG-AAAA-Hpu-AAAA-Hpu-AAAA-Hpu-A
P4 biotin-GG-AAAA-Hpu-AAAA-K-AAAA-Hpu-A
P5-Hpu GW-Hpu-PMSRSSGRVYYFNGG-K(biotin)
P5 GW-K-PMSRSSGRVYYFNGG-K(biotin)
P6-Hpu biotin-GGLLELD-Hpu-WASLW
P6 biotin-GGLLELD-K-WASLW
Crystallization
C1-Hpu GSG-Hpu-GSG
C2-Hpu GSG-deoxyHpu-GSG
PEG6, polyethylene glycol; Hpu, hypusine; deoxyHpu, deoxyhypu-
sine. The amino terminus of peptides is blocked by biotin as shown or
by an acetyl group (not shown). The carboxy terminus of peptides is
capped with biotin as shown or an amide group (not shown). Peptide
P2 is derived from the sequence of human eIF-5A.
604 Structural Analysis of Anti-Hypusine Antibodiesefforts to identify them. For example the search for
novel hypusinated proteins has included two-
dimensional gel electrophoresis of total protein from
different cells cultured in radiolabeled spermidine [1]
and, more recently, mass spectrometry using DHS or
DOOH proteins as baits [9].
Antibody-based affinity purification is widely used to
enrich low-abundance proteins for identification by
mass spectrometry. This approach has been success-
fully used for global analysis of protein lysine acetyla-
tion [10,11], arginine methylation [12], and tyrosine
phosphorylation [13,14]. However, high-affinity,
PTM-specific, and sequence-independent antibodies
are difficult to obtain for PTMsof interest because of the
small size of PTMs. In addition, there is no previously
reported complex structure of a PTM-specific, context-
independent antibody.
Several anti-hypusine or anti-deoxyhypusine
antibodies have been reported including polyclonal
[15,16] and monoclonal antibodies [17]. However,
the usage of these previously identified antibodies
may be limited for several reasons. Firstly, all
these antibodies were raised against eIF-5A pep-
tides and characterized against binding to eIF-5A.
Hence, theymay not bewell suited for identifying novel
hypusinated proteins with different sequences flanking
the hypusine. Secondly, the polyclonal antibodies
are not readily available and the sequences of the
monoclonal antibodies have not been reported.
Thirdly, the affinity of these anti-hypusine antibodies
has not been reported. As a result of these limitations
of existing anti-hypusine antibodies, radiolabeled
spermidine and GC7 (a DHS inhibitor) are still the
most frequently used tools for eIF-5A functional
studies.
We hypothesized that high-affinity monoclonal
antibodies that bind to hypusine independent of the
flanking amino acid sequences—referred to here as
context-independent anti-hypusine antibodies—
could be valuable tools for identifying novel hypusi-
nated proteins. To this end, we identified two types
of antibodies in this study: antibodies binding to
hypusine and deoxyhypusine and antibodies binding
to hypusine alone. These antibodies recognize
hypusine with minimal dependence on the surround-
ing amino acid sequences. The X-ray crystallographic
structures of the corresponding Fab fragments were
determined in complex with hypusine- or deoxyhypu-
sine-containing peptides. The hypusine or deoxyhy-
pusine moiety was found to reside in a deep pocket
formed between the VH and VL domains of the Fab
fragments. Based on the structures obtained, phage
display technology was used to further enhance the
affinity of the antibodies. Affinity maturation of these
anti-hypusine antibodies improved their performance
in affinity capture of hypusinated eIF-5A. Use of these
context-independent anti-hypusine antibodies to
search for novel hypusinated proteins is currently
ongoing.Results
Anti-hypusine antibody identification
and characterization
Our goal is to identify novel hypusinated proteins
using context-independent anti-hypusine antibodies
in conjunction with immunoprecipitation and mass
spectrometry. To support this goal, we identified
context-independent anti-hypusine antibodies that
bind to hypusine almost independently of the
surrounding amino acid sequences. Hypusine was
made as previously described [18] and used to
synthesize a panel of different hypusinated peptides
(Table 1). Ten rabbits were immunized alternately
with acetyl-hypusine-PEG6-C-amide (where PEG
represents polyethylene glycol) and acetyl-GSG-
hypusine-GSG-PEG6-C-amide peptides conjugated
to either keyhole limpet hemocyanin or thyroglobulin
(see Materials and Methods). After three rounds of
immunization, 4 out of 10 rabbits were pursued for
monoclonal antibody generation, as they showed a
slightly higher response to the hypusine-containing
peptides than their non-hypusinated counterparts by
ELISA.
Unpurified rabbit hybridoma supernatants were
screened by ELISA for selective binding to the
hypusinated peptides used for immunization and
605Structural Analysis of Anti-Hypusine Antibodiespositive wells further screened for binding to a panel
of different hypusinated peptides (Table 1). A total of
146 out of 7680 hybridoma supernatantswere found to
bind selectively to the hypusinated peptides used for
immunization, but not to corresponding non-hypusi-
nated peptides. Of these 146 hybridoma supernatants,
5 bound to all the hypusinated peptides with minimal
binding to corresponding non-hypusinated peptides.
These five rabbit monoclonal antibodies were molec-
ularly cloned, recombinantly expressed, purified, and
characterized.We confirmed that three out of these five
rabbit monoclonal antibodies,mAbHpu24,mAbHpu91,
and mAbHpu98, recognize all of the different hypusi-
natedpeptides, but not thecorrespondingnon-modified
peptides (Fig. 1a). These results suggest that these
anti-hypusine antibodies have the potential to interact
with many different hypusinated proteins, independent
of the flanking amino acid sequence and the secondary
structure environment of the hypusine.
Next, the anti-hypusine antibodies were character-
ized for their ability to bind to hypusine in the nativeFig. 1. mAbHpu24, mAbHpu91, and mAbHpu98 specificall
hypusinated peptides independent of flanking amino acid s
supernatants. The sequences of peptides (from P1 to P6)
overexpression of matured eIF-5A in 293 cells using a fu
hypusination. (c) Anti-hypusine antibodies specifically bind to
Western blot analysis. Endo-eIF-5A, endogenous eIF-5A.intact eIF-5A protein. Human embryonic kidney 293
cells were co-transfected with plasmids encoding flag-
tagged wild-type (or K50A variant) eIF-5A and myc-
tagged DHS fused to HA-tagged DOHH via a self-
cleaving T2A peptide linker [19] (Fig. 1b). Whole cell
lysates were subjected to SDS-PAGE and Western
blot analysis using anti-flag or anti-hypusine antibodies.
Wild-type and K50A mutant eIF-5A proteins were
expressed in similar amounts as judged by Western
blotting with anti-flag antibody (Fig. 1c). The three anti-
hypusine antibodies detected transfected wild-typeeIF-
5A, but not the K50A variant lacking the lysine required
for hypusination. The anti-hypusine antibodies also
recognized endogenous eIF-5A, the majority of which
is hypusinated [20].
Fine specificity characterization for anti-hypusine
antibodies
Next, the anti-hypusine antibodies were screened
for binding to the biosynthetic intermediate,y recognize hypusine. (a) Anti-hypusine antibodies bind to
equences as shown by ELISA of unpurified hybridoma
are provided in Table 1. (b) Construct design for the
sion protein of enzymes DHS and DOHH required for
hypusine in the native intact protein eIF-5A as shown by
606 Structural Analysis of Anti-Hypusine Antibodiesdeoxyhypusine (Fig. 2a). Only FabHpu98 bound
deoxyhypusine (Fig. 2b), although FabHpu91 differs
from FabHpu98 by only eight amino acids in the
variable domains (Fig. S2).
Single amino acid residues from FabHpu91 were
introduced at equivalent positions in FabHpu98 to
understand thebasis for the deoxyhypusine specificity.
The FabHpu98 Y52W variant prefers hypusine to
deoxyhypusine similar to FabHpu91, as judged by
biolayer interferometry (Fig. 2c). The FabHpu91W52Y
variant was constructed and found to have improved
ability to bind to deoxyhypusine and attenuated ability
to bind hypusine. Thus, VH Y52 can function as a
switch that determines binding specificity for hypusine
and deoxyhypusine.
FabHpu24-hypusinated peptide complex
An X-ray crystallographic structure of FabHpu24-
hypusinated C1 peptide complex was determined at
1.85 Å resolution to gain molecular insight into
antibody binding to hypusine (Table 2). The complex
crystallized in space group P21 with two very similarFig. 2. Antibody hypusine/deoxyhypusine fine specificity char
(b) FabHpu24 and FabHpu91 exclusively interact with hyp
deoxyhypusine. Binding analysis was undertaken using an
hypusinated P1 peptide (Table 1, magenta), deoxyhypusinated
streptavidin biosensors and then dipping into 200 nManti-Hpu F
dual binding to deoxyhypusine and hypusine.FabHpu24–hypusine complexes in the asymmetric
unit [root-mean-square deviation (RMSD) of 0.308 Å].
The 4-amino-2-hydroxybutyl group of the hypusine but
not the rest of the hypusine moiety is clearly visible in
the simulated annealing mFo − dFc omit electron
density map (Fig. S3a). These observations suggest
that FabHpu24 binds only to hypusine and not to
flanking amino acid residues. Indeed, hypusine is
inserted into a deep pocket formed by the heavy-chain
and the light-chain variable domains of FabHpu24
(Fig. 3a). The hypusine-binding pocket buries a total
solvent-exposed surface area of ~301 Å2 with 112 Å2
and 189 Å2 contributed by VH and VL chains,
respectively.
The hypusine-binding pocket is composed primarily
of residues in complementarity-determining regions
(CDR) L1, L3, and H3. There are only three
heteroatoms on the side chain of hypusine available
for polar interactions (Fig. 2a). Inspection of the
hypusine–FabHpu24 interface reveals a network of
interactions at the distal end of hypusine—the 4-
amino-2-hydroxybutyl group—including hydrogen
bondand salt bridge interactions (Fig. 4a).Specifically,acterization. (a) Structures of hypusine and deoxyhypusine.
usine, while FabHpu98 can bind to both hypusine and
Octet RED instrument by immobilizing biotinylated and
P1 peptide (orange), or the unmodified P1 peptide (blue) on
ab fragments. (c) FabHpu98 residueVH Y52 is necessary for
Table 2. Data collection and refinement statistics.
Hypusine-FabHpu24 Hypusine-FabHpu24.B Hypusine-FabHpu98 Deoxyhypusine-FabHpu98 Hypusine-FabHpu98.61
Data collection
Space group P21 P21 C222 C222 C2
Cell dimensions
a, b, c (Å) 42.4, 167.3, 68.3 69.1, 168.0, 84.9 106.0, 294.1, 68.7 105.6, 294.0, 68.8 130.1, 75.8, 120.6
α, β, γ (°) 90, 98.9, 90 90, 99.7, 90 90, 90, 90 90, 90, 90 90, 120.7, 90
Resolution (Å) 50–1.85 (1.92–1.85)a 50–2.40 (2.49–2.40)a 50.0–1.95 (2.0–1.95)a 50.0–2.0 (2.07–2.00)a 40.0–1.9 (2.0–1.9)a
Rsym (%) 6.6 (54.5)
a 7.4 (52.9)a 7.5 (78.5)a 7.5 (88.4)a 9.0 (55.2)a
CC1/2 in the highest shell 0.719 0.776 0.615 0.605 0.808
〈I〉/〈σ(I)〉 30.7 (2.0)a 15.4 (2.3)a 22.0 (2.2)a 16.0 (2.2)a 9.9 (2.1)a
Completeness (%) 99.9 (99.9)a 100 (99.9)a 99.8 (99.0)a 99.9 (99.8)a 97.7 (95.3)a
Redundancy 3.8 (3.6)a 1.9 (1.9)a 7.4 (6.5)a 7.1 (5.6)a 3.4 (3.3)a
Refinement statistics
Resolution (Å) 43.0–1.85 49.0–2.4 41.2–1.95 42.9–1.95 37.2–1.9
No. of unique reflections 79,471 73,996 78,403 74,438 77,821
No. of Fab fragments 2 4 2 2 2
No. of bound peptides 2 4 1 1 2
Rwork/Rfree (%) 19.1/22.1 20.7/24.2 18.2/22.4 18.1/22.0 21.2/25.4
No. of atoms
Protein 6422 12,779 6346 6429 6304
Solvent 354 276 242 235 322
RMSD
Bond lengths (Å) 0.008 0.004 0.011 0.011 0.005
Bond angles (°) 1.207 0.913 1.303 1.344 0.843
Ramachandran plot
Favored (%) 96.47 96.08 97.09 97.0 98.19
Allowed (%) 3.41 3.8 2.78 2.77 1.56
Outliers (%) 0.12 0.12 0.12 0.24 0.24
PDB identifier 5DRN 5DSC 5DS8 5DUB 5DTF
a Values in parentheses are for the highest-resolution shell.
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Fig. 3. Alternative binding modes
of FabHpu24 and FabHpu98 with
hypusine. (a) FabHpu24 Fab VL
(salmon) and VH (blue) domains
complexed to the hypusine-
containing peptide, C1-Hpu (yellow;
see Table 1). (b) FabHpu98 VL
(violet) and VH (teal) complexed to
the C1-Hpu peptide (yellow).
608 Structural Analysis of Anti-Hypusine Antibodiesthe first heteroatom (11-N) in the terminal amino group
of hypusine is likely positively charged under crystal-
lization conditions because its predicted pKa is 9.8 by
analytic continuumelectrostatics [21]. The heteroatom
(11-N) is anchored by a salt bridge with VL D96 at the
bottom of the pocket and two additional hydrogen
bonds to the side chain of VL D95 and the main-chain
carbonyl group of VH Y92. Additionally, VL D96 is
stabilized by VH Y100b and VL Y92 through hydrogen
bonds. The second heteroatom, the 9-hydroxyl group
of hypusine, forms hydrogen bonds to VL D95, VH
Y100b, and a water molecule. Furthermore, the water
molecule, coordinated by VH D100, also interacts with
the third heteroatom (7-N), whose predicted pKa is
10.2 and that also forms a hydrogen bond to the
carbonyl group of VL Y93. By contrast, the proximal
end of hypusinemay bemore flexible as suggested by
sparse electron density. This is not surprising because
the aliphatic chain is presumably only constrained by
hydrophobic interactions. Nevertheless, the proximal
portion of hypusine functions as a spacer, allowing the
distal end to reach the bottom of the binding pocket.
FabHpu98 hypusine and deoxyhypusine complex
FabHpu98 has dual specificity in that it can bind to
both hypusine and deoxyhypusine. The FabHpu98–
hypusine and FabHpu98–deoxyhypusine complex
crystals grew under the same conditions, and their
X-ray crystallographic structureswere both determined
at 2.0 Å resolution (Table 2). The complexes crystal-
lized in space group C222 with two similar FabHpu98
molecules in the asymmetric unit (RMSD of 1.243 Å).
One FabHpu98 molecule forms a complex withhypusine or deoxyhypusine while the other FabHpu98
molecule is uncomplexed, since its paratope is blocked
by intermolecular contacts.
In the FabHpu98 complex, hypusine or deoxyhypu-
sine also binds in a deep pocket constituted by the
VH and VL interface, with 148 Å
2 and 156 Å2 of
buried surface area of VH and VL chains, respectively
(Fig. 3b). Hypusine is tilted to slide down into the
binding pocket of FabHpu98 but is nearly vertical to
project between the variable domains of FabHpu24.
The two hypusine moieties project at an angle of 46°
with respect to each other.
In the FabHpu98–hypusine complex, the 4-amino-2-
hydroxybutyl group is also completely buried and
coordinated by electrostatic interaction and hydrogen
bonds, while the rest of hypusine is semi-buried. At the
bottom of the pocket, the terminal amino group (11-N)
of hypusine forms hydrogen bonds with VH framework
residuesN35 andD95 and an orderedwatermolecule.
The terminal amino group also interacts with VH
D50 through an electrostatic interaction. All of these
contacting residues are further positioned through a
hydrogen bond network with neighboring residues
(Fig. 4b). The heteroatom (7-N) forms hydrogen bonds
with the carbonyl group of VL Y92 and a sulfate ion.
The latter is dispensable in specificity andaffinity, since
surface plasmon resonance (SPR) experiments using
Hepes and Tris buffers showed that FabHpu98 binds
to hypusine or deoxyhypusine with similar affinities.
Aromatic residues apparently provide a favorable
hydrophobic environment for the aliphatic portion of
hypusine or deoxyhypusine. Unlike the FabHpu24–
hypusine complex, the nearby residues are also
revealed in the simulated-annealing mFo − dFc omit
Fig. 4. Hydrogen bond network for antibody–hypusine interaction. (a) Extensive hydrogen bond network of FabHpu24
with the hypusine-containing peptide, C1-Hpu. Stereo views showing VH (blue), VL (salmon), and C1-Hpu peptide (yellow)
with putative hydrogen bonds indicated by broken lines (orange) with lengths in Ångström as indicated. (b) Extensive
hydrogen bond network of FabHpu98 VH (magenta) and VL (teal) with the C1-Hpu peptide (yellow).
609Structural Analysis of Anti-Hypusine Antibodieselectron density map (Fig. S3b). Our model showed
that only peptide backbone atoms make contact with
FabHpu98.
Comparison of antibody interaction with
deoxyhypusine and hypusine
Hypusine and deoxyhypusine adopt similar confor-
mations to insert into the deep pocket constituted
by FabHpu98. However, there are differences in
deoxyhypusine and hypusine interaction. Firstly, thehydroxyl group of hypusine was unambiguously
revealed in theFo(hypusine) − Fo(deoxyhypusine) difference
map, which is calculated by using phases from the
FabHpu98:hypusine model (Fig. 5a). The hydroxyl
group of hypusine forms a hydrogen network with VL
S94, VH Y52, and a sulfate ion (Fig. 5b).
As described above, VH Y52 is indispensable for
deoxyhypusine interaction. The hydroxyl group of the
hypusine forms two relatively longhydrogenbondswith
VL S94 (3.0 Å) and VH Y52 side chains (3.0 Å)
(Fig. 5b). While in the FabHpu98–deoxyhypusine
610 Structural Analysis of Anti-Hypusine Antibodiescomplex, the twohydrogenbonds to the hydroxyl group
no long exist. Instead, VH Y52 displayed side-chain
movement and projects toward VL S94 and apparently
forms a (2.8 Å) hydrogen bond (Fig. 5c). These
observations are consistent with the mutagenesis and
SPR studies. The VH Y52F mutant displayed weaker
binding affinity to hypusine-containing peptides, com-pared towild-typeFabHpu98 (Fig. 2c), likely due to loss
of a hydrogen bond. Furthermore, the VH Y52F
mutation abolished detectable interaction with deox-
yhypusine likely because of its inability to form a
hydrogen bond with VL S94. Thus, VH residue Y52
plays a pivotal role in interaction with deoxyhypusine.
Affinitymaturationof the anti-hypusineantibodies
The binding affinity (Kd) of FabHpu98 and FabHpu24
to the P1 hypusinated peptide is ~119 nM and
~192 nM, respectively (Table 3). Previous studies
have shown that the eIF-5A is an abundant hypusi-
nated protein in many different cell types [1]. Higher-
affinity antibody binding to hypusine seems desirable, if
not necessary to increase the likelihood of identifying
low-abundance hypusinated proteins.
To potentially better support the core hydrogen
bond network for anchoring hypusine, we focused
engineering on peripheral CDR residues. Based on
the structures of complexes, CDRs L1, L2, and H2 of
FabHpu24 and CDRs H1, H2, and L3 of FabHpu98
were diversified in phage display libraries. Briefly, for
each library, seven consecutive positions on the
individual CDRs were mutated using degenerate
oligonucleotides (see Materials and Methods). We
also generated CDR combination libraries in which
residues in four different CDRs were simultaneously
mutated (H1, H2, L1, and L2). After 4–5 rounds of
phage library selection using biotin-PEG6-GSG-
hypusine-GSG (P1) peptide, enrichmentwas observed
for FabHpu24 CDR H2 and CDR combination libraries
and for FabHpu98 CDR H1 library. A total of 96
clones from each of these three libraries were then
sequenced. Generation of sequence frequency logos
using WebLogo [22] revealed significant sequence
diversity for the FabHpu24 CDR H2 and FabHpu98
CDR H1 libraries (Fig. 6). By contrast, a single clone
dominated the output from the FabHpu24 CDR
combination library. All unique clones identified were
expressed in Expi293 cells as Fab fragments, purified
and tested by SPR for binding to hypusinated P1
peptide.
Affinity-matured variant, FabHpu24.B, was derived
by combining mutations from other affinity-maturedFig. 5. Comparison of hypusine and deoxyhypusine
binding to FabHpu98. (a) The isomorphous Fo − Fo differ-
ence map showing the position of the hydroxyl group of
hypusine and shift of VH Y52 side chain, displayed at 5.0 σ.
(b) In the FabHpu98–hypusine complex, the hydroxyl group
of hypusine forms hydrogen bonds with both VL S94 and VH
Y52. (c) In the FabHpu98–deoxyhypusine complex, VL S94
and VH Y52 form a hydrogen bond. For both hypusine and
deoxyhypusine complexed with FabHpu98, the heteroatom
(7-N) forms hydrogen bonds with the carbonyl group of VL
Y92 and a sulfate ion. The sulfate ion is dispensable in
specificity and affinity as judged by SPR experiments using
Hepes and Tris buffers demonstrating that FabHpu98 binds
to hypusine or deoxyhypusine with similar affinities.
Table 3. Binding constants for context-independent anti-hypusine Fab fragments with peptides.
Peptide FabHpu24
Kd (nM)
FabHpu24.B
Kd (nM)
Fold improvement FabHpu98
Kd (nM)
FabHpu98.61
Kd (nM)
Fold
improvement
P1-Hpu 192 ± 35 6 ± 2 32 119 ± 60 15 ± 3 7.9
P1-deoxyHpu N1000 N1000 118 ± 61 17 ± 4 6.9
P1 N1000 N1000 N1000 N1000
P2-Hpu 157 ± 12 13 ± 5 12 204 ± 40 78 ± 14 2.6
P2-deoxyHpu N1000 N1000 158 ± 13 86 ± 22 1.8
P2 N1000 N1000 N1000 N1000
P3-Hpu N1000 186 ± 60 N5 N1000 N1000
P3 N1000 N1000 N1000 N1000
P4-Hpu 541 ± 331 32 ± 15 17 228 ± 43 91 ± 16 2.5
P4 N1000 N1000 N1000 N1000
P5-Hpu 96 ± 19 7 ± 3 13 176 ± 33 70 ± 21 2.5
P5 N1000 N1000 N1000 N1000
P6-Hpu 176 ± 55 61 ± 11 2.9 N1000 229 ± 40 N4.4
P6 N1000 N1000 N1000 N1000
Hpu, hypusine; deoxyHyu, deoxyhypusine. Affinity measurements (mean ± standard deviation) were made by SPR. Fold improvement in
binding affinity was calculated as the ratio of Kd values of the parent and corresponding affinity-matured antibodies. Peptide sequences
are provided in Table 1. Peptide P2 is derived from the sequence of human eIF-5A.
611Structural Analysis of Anti-Hypusine Antibodiesvariants of FabHpu24. FabHpu24.B contains 12 amino
acid replacements compared to the FabHpu24 paren-
tal clone (Fig. S1). FabHpu24.B has 32-fold higher
binding affinity than its parental clone for the hypusi-
nated P1 peptide (Table 3). FabHpu24.B maintainsFig. 6. Sequence frequency logos [22] of the clone pools
selected from the affinity maturation phage libraries. (a) CDR
H2sequences for FabHpu24and theaffinity-matured variant,
FabHpu24.B with sequence differences highlighted by
underlining. FabHpu24.B includes additional sequence
changes in CDRs L1 and L2 (Fig. S1). (b) CDR H1
sequences for FabHpu98 and the affinity-matured variant,
FabHpu98.61, with sequence differences highlighted by
underlining. Complete variable domain sequences of these
anti-hypusine clones are provided in Fig. S1 and Fig. S2.specificity to hypusine with a Kd value of 6 nM for
the hypusinated P1 peptide with no detectable binding
to the corresponding deoxyhypusinated P1 peptide
(Table 3 and Fig. S4). FabHpu98.61 was the highest-
affinity clone identified with low background in SPR
derived from FabHpu98. FabHpu98.61 differs from
its parent clone by five amino acid replacements in
CDR H1 (Fig. S2 and Fig. 6) including two cysteine
replacements, C27 and C32, subsequently shown to
form a disulfide bond (Fig. 7). FabHpu98.61 exhibited
similar high-affinity binding to both hypusinated P1
peptide (15 nM Kd) and deoxyhypusinated P1 peptide
(17 nM Kd) (Table 3).
Next, the affinity-matured cloneswere characterized
for binding to additional hypusinated peptides to
assesswhether increased affinitywasdue to improved
interaction with hypusine or to flanking sequences
(Table 3). FabHpu24.B shows 3- to 32-fold increased
binding affinity to each of the hypusinated peptides
compared to the parent Fab fragment with no
detectable binding to corresponding unmodified pep-
tides or deoxyhypusinated peptides (where tested).
FabHpu98.61 demonstrated 2- to 8-fold increased
binding affinity to each of the hypusinated peptides
compared to its FabHpu98 parent with no detectable
binding to corresponding unmodified peptides. Addi-
tionally, FabHpu98.61 binds to deoxyhypusinated P1
and P2 peptides with 2- to 7-fold affinity improvement
compared to the parent clone. The anti-hypusine
antibodies have a slight sequence preference; for
example, FabHpu98.61 shows minimal binding to
hypusinated P3 peptide, whereas it binds more tightly
to other peptides (Table 3 and Fig. S6). FabHpu24.B
has the highest-affinity binding to the hypusinated
peptides, while FabHpu98.61 retains the ability to
bind to deoxyhypusinated peptides. Hence, the
combination of FabHpu24.B and FabHpu98.61 ap-
pears suitable for the discovery of different hypusine-
modified and deoxyhypusine-modified proteins.
Fig. 7. Structure of affinity-matured Fab fragments binding to hypusine. (a) Comparison of FabHpu24 VL (salmon) and
VH (blue) and FabHpu24.B VL (salmon) and VH (green) binding to C1-Hpu peptide (GSG-Hpu-GSG, yellow).
Conformational change in CDRs H2 and H3 increases the contact area for hypusine interaction. (b) Extensive hydrogen
bond network of FabHpu24.B with the C1-Hpu peptide. (c) Comparison of FabHpu98 VL (violet) and VH (cyan) and
FabHpu98.61 VL (violet) and VH (green) binding to C1-Hpu peptide (GSG-Hpu-GSG). (d) Residue T33 of FabHpu24.B
makes an additional hydrogen bond with hypusine.
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The crystal structure of FabHpu24.B-hypusinated
C1-Hpu peptide complex was determined at 2.4 Å
resolution (Table 2) to better understand the
molecular basis for the affinity improvement of
FabHpu24.B. The crystal packing of FabHpu24.B
is similar to that of FabHpu24 despite the unit cell
being twice as big as that of FabHpu24. The amino
acid sequence of FabHpu24.B differs from its parent
FabHpu24 by five, four, and three replacements in
CDRs L1, L2, and H2, respectively (Fig. S1). By
contrast, the backbone conformational change is
observed only in CDR H2, which further pushes CDR
H3 toward the hypusine moiety (Fig. 7a). Conse-
quently, a hydrogen bond between FabHpu24.B VH
D100 and VL Y28 creates a larger contact area to
embrace hypusine (Fig. 7b). Hypusine is apparently
anchored in the deep pocket with the same hydrogen
network, except that the third heteroatom (7-N)
directly forms a hydrogen bond with the carbonyl
group of VH G100a in FabHpu24.B, instead of the
coordinated water (Fig. 7b). Furthermore, the flanking
residues adjacent to hypusine are also involved in the
interaction with FabHpu24.B. The carbonyl group of
VH M99 and the VH D56 side chain form hydrogen
bonds with the backbone of the C1-Hpu peptide.
Additionally, VH residue D56 also interacts with the
side chain of the flanking residue in peptide S6. These
results may account for the difference in binding
affinities between FabHpu24.B and hypusine with
different flanking sequences with Kd values varying
from 6 nM to 186 nM. Although only hypusine is
observed in the FabHpu24–hypusine complex, the
flanking sequences also impact the interaction
between FabHpu24 and hypusine. Nevertheless,
FabHpu24.B is able to bind to all six hypusinated
peptides tested (Table 3).Fig. 8. Affinity-matured anti-hypusine antibodies give improv
blue staining showing that more endogenous eIF-5A wa
mAbHpu24.B than the parent antibody, mAbHpu24. (b) Co
eIF-5A was immunoprecipitated by the affinity-matured antiboFabHpu98.61 complexwith a hypusinated peptide
AnX-ray crystallographic structure of FabHpu98.61-
hypusinated C1 peptide complex was determined at
1.9 Å resolution (Table 2) to gainmolecular insight into
antibody binding to hypusine. The complex crystallized
in space groupC2with two very similar FabHpu98.61–
hypusine complexes in the asymmetric unit (RMSD of
0.241 Å). FabHpu98.61 and FabHpu98 bind to the
hypusinated C1 peptide in very similar manner, except
for CDRH1, within whichC27 andC32 form a disulfide
bond (Fig. 7c and d). As a result, FabHpu98.61 CDR
H1 leans toward VHW97 and may improve its packing
against hypusine. In addition, VH T33 moves closer
and forms an additional hydrogen bond with 11-N of
hypusine, whose other interactions remain the same
(Fig. 7d).
Improved recoveryof eIF-5Ausingaffinity-matured
anti-hypusine antibodies
FabHpu24.B and FabHpu98.61, the affinity-
matured antibodies in Fab format, showed ~12-fold
and ~3-fold higher binding affinity for the hypusinated
eIF-5A peptide (P2-Hpu) than their corresponding
parent Fab fragments, respectively (Table 3). To study
whether affinity-matured antibodies in IgG format
would enhance the efficiency of immunoprecipitation
of potential hypusinatedproteins,weusedmAbHpu24,
mAbHpu24.B, mAbHpu98, and mAbHpu98.61 to
recover endogenous eIF-5A protein from a 293T cell
lysate. The parental antibody, mAbHpu24, immuno-
precipitated eIF-5A over a range of lysate dilutions,
while the affinity-matured variant, mAbHpu24.B, en-
hanced the recovery of eIF-5A by ≥3-fold down to
b1 μg/ml (Fig. 8). Furthermore, mAbHpu98.61 also
outperformed mAbHpu98 in recovering eIF-5A
(Fig. 8), even though mAbHpu98.61 has only 2.6-folded recovery of hypusinated protein, eIF-5A. (a) Coomassie
s immunoprecipitated by the affinity-matured antibody,
omassie blue staining showing that more endogenous
dy, mAbHpu98.61, than the parent antibody mAbHpu98.
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peptide (Table 3). Therefore, affinity-matured context-
independent hypusine antibodies may be more
efficient to enrich potential novel hypusinated proteins
that are present in low abundance.Discussion
Here, we have developed and structurally plus
functionally characterized high-affinity antibodies that
bind to hypusinated peptides or hypusinated and
deoxyhypusinated peptides with minimal dependence
on flanking amino acid sequences. These context-
independent anti-hypusine antibodies may have utility
in the identification of novel hypusinated or deoxyhy-
pusinated proteins with potentially different hypusine-
flanking sequences to the only reported hypusinated
protein, eIF-5A.
X-ray crystallographic studies revealed that anti-
body binding to hypusine utilizes a deep cleft
between the VL and VH domains, which is similar
to antibody interactions with small molecule haptens
[23,24]. Although FabHpu24 was crystallized with a
hypusinated peptide (C1-Hpu), only hypusine and
not the flanking residues were visible in the structure.
By contrast, several amino acids surrounding
hypusine within the C1-Hpu peptide were revealed in
the complexes with the affinity-matured FabHpu24.B.
There are several possible reasons for this difference
between parent and affinity-matured antibodies.
Firstly, the conformational change in CDR H2 and H3
loops of FabHpu24.B results in novel contacts with
flanking residues, which are absent in FabHpu24.
Secondly, higher concentration of the peptide under
crystallization condition and additional peptide into
the cryoprotectant of later FabHpu24.B enhanced the
occupancy of the peptide. In complex structures
of FabHpu98 and FabHpu98.61 with the C1-Hpu
peptide, hypusine is still the major contact (65%
interface), while flanking amino aids comprise ~35%
of the surface area of the interface. The structures are
consistent with the SPR results that the flanking amino
acids have an impact on hypusine interaction with the
above Fab fragments. However, these anti-hypusine
Fab fragments can bind to all of the different
hypusinated peptides tested (Table 3), and the
presence of hypusine is critically required for antibody
binding.
Similar to previously reported rabbit Fab structures,
the κ inter-chain disulfide bond between VL C80
and VL C170 is located in the elbow region [25–27].
In addition, a non-canonical disulfide bond was
observed involving residues VH residues C27 and
C32 within CDR H1 of the affinity-matured antibody,
FabHpu98.61. This disulfide bond changes the
conformation of CDR H1 and that may contribute to
the higher-affinity binding to hypusine-containing
peptides. Understanding the molecular basis of theincreased affinity for affinity-matured clones will
require further mutagenesis studies.
The structures reported here are, to our knowledge,
the first structures of context-independent (pan-)
antibodies in complexwith a PTMof interest. Although
pan-anti-trimethyllysine [28], pan-anti-acetylation
[10,11], and pan-anti-phosphotyrosine antibodies
[13,14] have been generated, as well as numerous
peptide-specific anti-PTM antibodies, there are no
structures of pan-PTM antibodies available, as well
as a only a few structures of antibodies in complexes
with phosphorylated peptides [29,30]. The structures
reported here can potentially serve as antibody
scaffolds to generate other context-independent
anti-PTM antibodies, as well as sequence-specific
anti-hypusine antibodies. To generate sequence-
specific anti-hypusine antibodies, we can randomize
the peripheral CDR residues of mAbHpu24 and
mAbHpu98 to create binding sites for the amino
acids flanking the hypusine modification.
The context-independent anti-hypusine antibodies
described here bind selectively to the hypusine moiety
with highaffinities. Theseantibodiesappearwell suited
for the identification of other proteins with hypusine
(or closely related modifications). In addition, these
antibodies can be utilized to track hypusinated eIF-5A,
since eIF-5A is themost abundant hypusinated protein
in many cells. In higher eukaryotes, both the DHS
and DOHH genes are essential, their homologous
genes have been identified in yeast, and eIF-5Amainly
exists as the hypusine-containing mature form in cells.
However, a DOHH-null Saccharomyces cerevisiae
strain is still viable, although it grows slightly slower
than the wild-type strain, suggesting that deoxyhypu-
sine-eIF-5A is functional in yeast [3]. These observa-
tions indicate that deoxyhypusine might function as a
PTM on its own in some circumstances.Materials and Methods
Antibody generation, expression, and purification
Hypusinatedpeptideswere synthesizedusingapreviously
published method [18]. To generate context-independent
anti-hypusine antibodies, we immunized 10 rabbits with a
cocktail of keyhole limpet hemocyanin or thyroglobulin-
conjugated I1-Hpuand I2-Hpupeptides (YenZymAntibodies,
South San Francisco, CA) (see Table 1 for peptides). After
three rounds of immunization with 3 weeks between boosts,
rabbits were screened by ELISA for their selectivity of binding
to hypusine-containing peptides over corresponding non-
hypusinated peptides. Four rabbits with the highest selectivity
of binding were subjected to one additional round of
immunization. Rabbit monoclonal antibodies were then
generated (Abcam, Burlingame, CA) [31]. Supernatants
from hybridoma wells were screened by ELISA for binding
to hypusinated and matched non-hypusinated peptides
(Table 1). Five hybridoma clones, which were able to bind
all the hypusinated peptides with flanking sequences, for
615Structural Analysis of Anti-Hypusine Antibodiesexample, hypusinated eIF-5A peptide, were selected for
further characterization.
The antibody sequences were obtained by extracting
RNA using RNeasy Mini Kit, reverse transcription using
SuperScript III RT-PCR system, amplification using a
SMARTer RACER 5′ kit (Clontech Laboratories), and TA
cloning. CHO cells were transfected with plasmid and
cultured for 2 weeks. IgGmolecules were purified by protein
A affinity chromatography (5-ml HiTrap MabSelect SuRe
column; GEHealthcare). The Fab fragments were prepared
by papain digestion. The IgGmolecules were incubatedwith
papain at a 20:1 molar ratio in 20 mM phosphate (pH 6.5),
150 mM NaCl, 20 mM cysteine hydrochloride, and 4 mM
ethylenediaminetetraacetic acid (EDTA). After 4 h at 37 °C,
the reaction was quenched by the addition of 30 mM
iodoacetamide. The Fab fragments were separated from
the Fc fragments and the undigested IgG by MabSelect
SuRechromatography and harvesting the flow-through. The
Fab fragments were further purified on a SuperDex D75
column (GE Healthcare) in 10 mM Tris–HCl 8.0 and
100 mM NaCl.Specificity of anti-hypusine antibodies to eIF-5A
Flag-tagged human WT or K50A eIF-5A was expressed
in human embryonic kidney 293T cells together with myc-
tagged DHS and HA-tagged DOHH. Transfected 293T
cells were lysed in lysis buffer [50 mM Tris–HCl, 150 mM
NaCl, 2 mM EDTA, 1% Triton-X100, and protease inhibitor
cocktail (pH 7.4)]. The supernatant were collected after
centrifugation (30 min, 16,000g, and 4 °C). Samples were
then analyzed by Western blotting to determine the
specificity of each anti-hypusine monoclonal antibody.X-ray crystallographic structural analysis
Purified FabHpu24 was concentrated to 10 mg/ml and
mixedwith acetyl-GSG-hypusine-GSG-amide peptide at 1:2
molar ratio before crystallization by the sitting-drop method.
The optimized crystallization condition for complexes of
FabHpu24 was 20% PEG 3350, 0.1 M bis-Tris propane
(pH 7.0), and 0.2 M potassium/sodium phosphate at 4 °C.
For data collection, crystals were soaked briefly in the
cryoprotectant solution [25% glycerol, 20% PEG 3350,
0.1 M bis-Tris propane (pH 7.0), and 0.2 M potassium/
sodium phosphate] before flash-cooling in liquid nitrogen.
Diffraction data were collected using beamline ALS 5.0.2 at
the Advanced Light Source synchrotron in Berkeley, CA.
Purified FabHpu24.B was concentrated to 10 mg/ml and
mixed with acetyl-GSG-hypusine-GSG-amide peptide
(C1-Hpu) at 1:4 molar ratio before crystallization by the
sitting-drop method. The optimized crystallization condition
for complexes of FabHpu24.B was 14% PEG 6000 and
0.5 M NaCl at 19 °C. For data collection, crystals were
soaked briefly in the cryoprotectant solution (35% ethylene
glycol, 14% PEG 6000, 0.5 M NaCl, and 1 mM C1-Hpu
peptide), before flash-cooling in liquid nitrogen. Diffraction
data were collected using beamline 5.0.2 at the Advanced
Light Source synchrotron in Berkeley.
Purified FabHpu98 was concentrated to 15 mg/ml and
mixed with acetyl-GSG-hypusine-GSG-amide peptide
(C1-Hpu) or acetyl-GSG-deoxyhypusine-GSG peptide
(C2-Hpu) at 1:4 molar ratio before crystallization by thesitting-drop method. The optimized crystallization condition
for complexes of FabHpu98 was 20% PEG 8000 and 0.5 M
Li2SO4 at 4 °C. For data collection, crystals were soaked
briefly in the cryoprotectant solution (30% ethylene glycol,
5% PEG 8000, 0.4 M Li2SO4, 30% ethylene glycol, and
1 mM of the corresponding peptide), before flash-cooling in
liquid nitrogen, and the data set was collected using
beamline 22-IDG at the Advanced Photon Source synchro-
tron in Chicago, IL.
All X-ray diffraction data sets were processed with the
HKL2000 software package [32]. The structures were
determined by molecular replacement with Phaser in the
PHENIX software package with a starting model built on a
homologous Fab [Protein Data Bank (PDB) ID 4HBC]
[33,34].Phage display for affinity maturation
To improve phage display of rabbit FabHpu24 and
FabHpu98 in Escherichia coli, we synthesized the bacteria
codon-optimized rabbit FabHpu24andFabHpu98sequences
(Genewiz) and cloned them into the phage display vector.
Phage display libraries were generated by Kunkel mutagen-
esis [35]. In each library, seven consecutive positions in the
sameCDR loopsweresubjected to site-directedmutagenesis
using degenerate oligonucleotides synthesized with 70%/
10%/10%/10%mixtures of the four nucleotide bases with the
wild-type nucleotide being used in excess. Multiple libraries
were constructed to cover the whole CDR for CDRs longer
than seven residues. Consequently, the resulting library
favors wild-type residues with a frequency of approximately
50%. All phage preparation was performed according to
standard protocols [36]. Briefly, 96-well Maxisorp plates were
coated with 5 μg/ml NeutrAvidin overnight at 4 °C and
subsequently blocked with Superblock™ T20 (phosphate-
buffered saline) blocking buffer for 1 h at 20 °C. For round 1,
P1-Hpu peptide was captured on the plate after 10 min
shaking with 500 nM peptide. After removing excess peptide,
we added 100 μl library phage (3 × 1012 particles permilliliter
in blocking buffer) to each well and the plates were incubated
for 1 h at room temperature. The plates were then washed 10
times with 0.05% (v/v) Tween 20 in phosphate-buffered
saline. Bound phage were eluted from the plates with
0.1 M HCl and 0.5 M KCl for 20 min, neutralized with an
equal volume of 1 M Tris–HCl (pH 7.5), and amplified for
subsequent rounds. From selection round 2 onwards,
Fab displaying phage was mixed first with a decreasing
concentration of biotinylated peptide and captured on the
NeutrAvidin-coated wells for 15 min. After several rounds,
selected clones were reformatted as IgG and transiently
transfected into Expi293 cells (Life Technologies, Grand
Island, NY).Measurement of peptide binding to Fab fragments
Detection of the interaction between peptides and Fab
fragments was conducted by biolayer interferometry using
the Octet RED 96 system (ForteBio, Menlo Park, CA). The
peptides were immobilized on streptavidin-coated sensor
tips (ForteBio). Prior to use, the sensor tips were soaked
for 1 min 1× kinetics buffer. The Fab fragments were
adjusted to a concentration of 200 nM. The microplates
used in the Octet were filled with 200 μl buffer or samples
616 Structural Analysis of Anti-Hypusine Antibodiesper well. Data were generated automatically by the Octet
Data Acquisition 7.0 software.
SPR data were measured on a Biacore model T200
(Biacore, Uppsala, Sweden). A Biacore CM5 chip was
coated with NeutrAvidin at ~300 RU and biotinylated
antigens were captured b10 RU. Serial dilutions of the
Fab fragments in 10 mMHepes (pH 7.4), 0.15 M NaCl, and
0.005% surfactant P20 were flowed over the immobilized
peptides and 1:1 Langmuir binding models were used to
calculate the kon, koff, and Kd for each Fab:antigen pair.
Immunoprecipitation of eIF-5A
Six plates (150 mm) of sub-confluent 293T cells were
harvested and lysed in 3 ml ice-cold lysis buffer [50 mM
Tris–HCl, 100 mM NaCl, 2 mM EDTA, 0.2% Triton-X100,
and protease inhibitor cocktail (pH 7.4)]. The supernatant
was collected after centrifugation (30 min, 50,000g, 4 °C)
and the eIF-5A concentration was quantified by ELISA. Cell
lysate samples (500 μl) containing different concentration
of eIF-5A (30, 10, 3, 1, 0.3, or 0.1 μg/ml) were added to
50 μl protein A Dynabeads (Invitrogen) preloaded with
10 μg purified mAbhpu24, mAbhpu24.B, mAbhpu98, or
mAbhpu98.61 and were incubated at 4 °C for 4 h. The
beads were then washed three times with lysis buffer and
incubated with 50 μl 1× NuPAGE LDS sample buffer at
70 °C for 10 min. Samples (10 μl) were then analyzed by
electrophoresis and visualized by Coomassie blue staining.
Accession numbers
Coordinates and structure factors have been deposited
in the PDB with accession numbers 5DRN, 5DSC, 5DS8,
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